Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

Sativex® as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

(2018) Jolana Markovà et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

An international survey of patients living with spasticity

(2016) Michael Barnes et al.   DISABILITY AND REHABILITATION

Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice

(2016) Patrick Vermersch et al.   EUROPEAN NEUROLOGY

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity

(2016) F Patti et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper

(2016) Susana Otero-Romero et al.   Multiple Sclerosis Journal

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper

(2016) Susana Otero-Romero et al.   Multiple Sclerosis Journal

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

(2016) Tilden Etges et al.   Therapeutics and Clinical Risk Management

Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity

(2014) Peter Flachenecker et al.   EUROPEAN NEUROLOGY

Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life

(2013) P. Flachenecker et al.   ACTA NEUROLOGICA SCANDINAVICA

Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study

(2013) Rafael Arroyo et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Spasticity in multiple sclerosis: results of a patient survey

(2013) C. Oreja-Guevara et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Épidémiologie et évaluation clinique de la spasticité dans la sclérose en plaques

(2012) D. Bensmail et al.   REVUE NEUROLOGIQUE

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

Health outcomes in economic evaluation: the QALY and utilities

(2010) S. J. Whitehead et al.   BRITISH MEDICAL BULLETIN

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

(2008) John T. Farrar et al.   CLINICAL THERAPEUTICS